{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:47:05Z","timestamp":1785916025608,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T00:00:00Z","timestamp":1624060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T00:00:00Z","timestamp":1624060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002342","name":"Suomalainen Tiedeakatemia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Atherosclerosis, defined by inflammation and accumulation of cholesterol, extracellular matrix, and cell debris into the arteries is a common factor behind cardiovascular diseases (CVD), such as coronary artery disease, peripheral artery disease, and stroke. In this review, we discuss and describe novel RNA interference (RNAi)-based therapies in clinical trials and on the market.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>The first RNAi-based therapies have entered clinical use for the control of atherosclerosis risk factors, i.e., blood cholesterol levels. The most advanced treatment is silencing of proprotein convertase subtilisin\/kexin type 9 (PCSK9) with a drug called inclisiran, which has been approved for the treatment of hypercholesterolemia in late 2020, and results in a robust decrease in plasma cholesterol levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>As the new RNAi therapies for atherosclerosis are now entering markets, the usefulness of these therapies will be further evaluated in larger patient cohorts. Thus, it remains to be seen how fast, effectively and eminently these new drugs consolidate their niche within the cardiovascular disease drug palette.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11883-021-00938-z","type":"journal-article","created":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T07:06:00Z","timestamp":1624086360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Novel RNAi-Based Therapies for Atherosclerosis"],"prefix":"10.1007","volume":"23","author":[{"given":"Anna-Kaisa","family":"Ruotsalainen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petri","family":"M\u00e4kinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7593-2708","authenticated-orcid":false,"given":"Seppo","family":"Yl\u00e4-Herttuala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,19]]},"reference":[{"issue":"6836","key":"938_CR1","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"SM Elbashir","year":"2001","unstructured":"Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001 May 24;411(6836):494\u20138.","journal-title":"Nature"},{"issue":"4","key":"938_CR2","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","volume":"3","author":"J Tabernero","year":"2013","unstructured":"Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013 Apr;3(4):406\u201317.","journal-title":"Cancer Discov"},{"key":"938_CR3","doi-asserted-by":"crossref","unstructured":"Second RNAi drug approved. Nat Biotechnol 2020;38(4):385-020-0494-3.","DOI":"10.1038\/s41587-020-0494-3"},{"key":"938_CR4","doi-asserted-by":"crossref","unstructured":"Scott LJ, Keam SJ. Lumasiran: First Approval. Drugs 2021 Jan 6.","DOI":"10.1007\/s40265-020-01463-0"},{"key":"938_CR5","doi-asserted-by":"crossref","unstructured":"Prakash TP, Graham MJ, Yu J, Carty R, Low A, Chappell A, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 2014 Jul;42(13):8796\u2013807.","DOI":"10.1093\/nar\/gku531"},{"issue":"49","key":"938_CR6","doi-asserted-by":"publisher","first-page":"16958","DOI":"10.1021\/ja505986a","volume":"136","author":"JK Nair","year":"2014","unstructured":"Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014 Dec 10;136(49):16958\u201361.","journal-title":"J Am Chem Soc"},{"issue":"12","key":"938_CR7","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1194\/jlr.R026658","volume":"53","author":"G Lambert","year":"2012","unstructured":"Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012 Dec;53(12):2515\u201324.","journal-title":"J Lipid Res"},{"key":"938_CR8","doi-asserted-by":"publisher","first-page":"595819","DOI":"10.3389\/fphys.2020.595819","volume":"11","author":"JL Katzmann","year":"2020","unstructured":"Katzmann JL, Gouni-Berthold I, Laufs U. PCSK9 inhibition: insights from clinical trials and future prospects. Front Physiol. 2020 Nov 16;11:595819.","journal-title":"Front Physiol"},{"issue":"12","key":"938_CR9","first-page":"158791","volume":"2020 Dec","author":"H Ruhanen","year":"1865","unstructured":"Ruhanen H, Haridas PAN, Jauhiainen M, Olkkonen VM. Angiopoietin-like protein 3, an emerging cardiometabolic therapy target with systemic and cell-autonomous functions. Biochim Biophys Acta Mol Cell Biol Lipids. 1865;2020 Dec(12):158791.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"938_CR10","doi-asserted-by":"crossref","unstructured":"Xu YX, Redon V, Yu H, Querbes W, Pirruccello J, Liebow A, et al. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. Atherosclerosis. 2018 Jan;268:196\u2013206.","DOI":"10.1016\/j.atherosclerosis.2017.08.031"},{"key":"938_CR11","doi-asserted-by":"crossref","unstructured":"Taskinen MR, Packard CJ, Boren J. Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD. Curr Atheroscler Rep 2019;21(8):27-019-0791-9. Excellent recent review in the raws 355-356.","DOI":"10.1007\/s11883-019-0791-9"},{"issue":"2","key":"938_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/qjmed\/93.2.75","volume":"93","author":"G Lippi","year":"2000","unstructured":"Lippi G, Guidi G. Lipoprotein(a): from ancestral benefit to modern pathogen? QJM. 2000 Feb;93(2):75\u201384.","journal-title":"QJM"},{"issue":"2","key":"938_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1194\/jlr.M078360","volume":"59","author":"H Sun","year":"2018","unstructured":"Sun H, Krauss RM, Chang JT, Teng BB. PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction. J Lipid Res. 2018 Feb;59(2):207\u201323.","journal-title":"J Lipid Res"},{"issue":"15","key":"938_CR14","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med. 2017;376(15):1430\u201340. A study showing that Inclisiran can be used for cholesterol lowering in patients with cardiovascular disease.","journal-title":"N Engl J Med"},{"issue":"22","key":"938_CR15","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.119.044431","volume":"141","author":"GK Hovingh","year":"2020","unstructured":"Hovingh GK, Lepor NE, Kallend D, Stoekenbroek RM, Wijngaard PLJ, Raal FJ. Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin\/kexin type 9 expression in homozygous familial hypercholesterolemia: the ORION-2 pilot study. Circulation. 2020 Jun 2;141(22):1829\u201331.","journal-title":"Circulation"},{"key":"938_CR16","doi-asserted-by":"crossref","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507\u201319.","DOI":"10.1056\/NEJMoa1912387"},{"issue":"16","key":"938_CR17","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330. Inclisiran is an effective, long-term therapy for the treatment of heterozygote familial hypercholesterolemia. Inclisiran reduced plasma LDL-C levels ~40% in comparison to placebo treated group of patients HeFH, with similar adverse effects.","journal-title":"N Engl J Med"},{"key":"938_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.amjcard.2020.08.018","volume":"134","author":"SA Khan","year":"2020","unstructured":"Khan SA, Naz A, Qamar Masood M, Shah R. Meta-analysis of inclisiran for the treatment of hypercholesterolemia. Am J Cardiol. 2020 Nov 1;134:69\u201373.","journal-title":"Am J Cardiol"},{"key":"938_CR19","doi-asserted-by":"crossref","unstructured":"Landmesser U, Haghikia A, Leiter LA, Wright RS, Kallend D, Wijngaard P, et al. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin\/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. Cardiovasc Res. 2021 Jan 1;117(1):284\u201391.","DOI":"10.1093\/cvr\/cvaa077"},{"key":"938_CR20","doi-asserted-by":"crossref","unstructured":"Wright RS, Collins MG, Stoekenbroek RM, Robson R, Wijngaard PLJ, Landmesser U, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies. Mayo Clin Proc. 2020 Jan;95(1):77\u201389.","DOI":"10.1016\/j.mayocp.2019.08.021"},{"key":"938_CR21","doi-asserted-by":"crossref","unstructured":"Lamb YN. Inclisiran: First Approval. Drugs 2021 23.","DOI":"10.1007\/s40265-021-01473-6"},{"key":"938_CR22","doi-asserted-by":"crossref","unstructured":"Ahmad Z, Banerjee P, Hamon S, Chan KC, Bouzelmat A, Sasiela WJ, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019 Aug 6;140(6):470\u201386.","DOI":"10.1161\/CIRCULATIONAHA.118.039107"},{"key":"938_CR23","doi-asserted-by":"crossref","unstructured":"Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017 Jul 20;377(3):222\u201332.","DOI":"10.1056\/NEJMoa1701329"},{"key":"938_CR24","doi-asserted-by":"crossref","unstructured":"Watts GF, Schwabe C, Scott R, Gladding P, Sullivan D, Baker J, et al. Abstract 15751: Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference targeting hepatic angiopoietin-like protein 3, in patients with hypercholesterolemia. Circulation. 2020;142:A15751. A conference abstract reporting that ANGPTL3 inhibition reduces plasma LDL-C and TG levels efficiently in familial hypercholesterolemia patients.","DOI":"10.1161\/circ.142.suppl_3.15751"},{"key":"938_CR25","doi-asserted-by":"crossref","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020 Aug 20;383(8):711\u201320.","DOI":"10.1056\/NEJMoa2004215"},{"issue":"7","key":"938_CR26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1161\/CIRCULATIONAHA.106.622514","volume":"114","author":"A Kawakami","year":"2006","unstructured":"Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation. 2006 Aug 15;114(7):681\u20137.","journal-title":"Circulation"},{"issue":"1","key":"938_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1161\/01.ATV.0000249620.68705.0d","volume":"27","author":"A Kawakami","year":"2007","unstructured":"Kawakami A, Aikawa M, Nitta N, Yoshida M, Libby P, Sacks FM. Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):219\u201325.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"938_CR28","doi-asserted-by":"crossref","unstructured":"Schwabe C, Scott R, Sullivan D, Baker J, Clifton P, Hamilton J, et al. RNA interference targeting apolipoprotein C-III with ARO-APOC3 in healthy volunteers mimics lipid and lipoprotein findings seen in subjects with inherited apolipoprotein C-III deficiency. European Heart Journal, Eur Heart J 2020;41(S2). A conference abstract reporting that ApoC-III inhibition reduces plasma TG levels efficiently in healthy volunteers.","DOI":"10.1093\/ehjci\/ehaa946.3330"},{"issue":"12","key":"938_CR29","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40265-019-01168-z","volume":"79","author":"J Paik","year":"2019","unstructured":"Paik J, Duggan S. Volanesorsen: First Global Approval. Drugs. 2019 Aug;79(12):1349\u201354.","journal-title":"Drugs"},{"key":"938_CR30","doi-asserted-by":"crossref","unstructured":"Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, et al. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med. 2015 Jul 30;373(5):438\u201347.","DOI":"10.1056\/NEJMoa1400283"},{"key":"938_CR31","doi-asserted-by":"crossref","unstructured":"Pechlaner R, Tsimikas S, Yin X, Willeit P, Baig F, Santer P, et al. Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III. J Am Coll Cardiol. 2017 Feb 21;69(7):789\u2013800.","DOI":"10.1016\/j.jacc.2016.11.065"},{"issue":"3","key":"938_CR32","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1161\/CIRCRESAHA.118.313171","volume":"124","author":"RA Hegele","year":"2019","unstructured":"Hegele RA, Tsimikas S. Lipid-lowering agents. Circ Res. 2019 Feb;124(3):386\u2013404.","journal-title":"Circ Res"},{"key":"938_CR33","doi-asserted-by":"crossref","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019 Aug 8;381(6):531\u201342.","DOI":"10.1056\/NEJMoa1715944"},{"issue":"33","key":"938_CR34","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","volume":"40","author":"VJ Alexander","year":"2019","unstructured":"Alexander VJ, Xia S, Hurh E, Hughes SG, O'Dea L, Geary RS, et al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J. 2019 Sep 1;40(33):2785\u201396.","journal-title":"Eur Heart J"},{"issue":"6","key":"938_CR35","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017 Feb 14;69(6):692\u2013711.","journal-title":"J Am Coll Cardiol"},{"key":"938_CR36","first-page":"1","volume":"300","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Stroes ESG. The dedicated \"Lp(a) clinic\": A concept whose time has arrived? Atherosclerosis. May. 2020;300:1\u20139.","journal-title":"May"},{"issue":"24","key":"938_CR37","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275\u201384. Lp(a) is considered an independent and one of the most significant risk factors of CVD. This meta-analysis reveals that statin therapy increase plasma Lp(a) levels ~20%. Further studies are required to clarify the effect on CVD risk in these patients.","journal-title":"Eur Heart J"},{"issue":"12","key":"938_CR38","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O'Donoghue","year":"2019","unstructured":"O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019 Mar 19;139(12):1483\u201392.","journal-title":"Circulation"},{"key":"938_CR39","doi-asserted-by":"crossref","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020 Jan 16;382(3):244\u201355.","DOI":"10.1056\/NEJMoa1905239"},{"key":"938_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/circ.142.suppl_3.13951","volume":"142","author":"MJ Koren","year":"2020","unstructured":"Koren MJ, Moriarty PM, Neutel J, Baum SJ, Hernandez-Illas M, Weintraub HS, et al. Abstract 13951: safety, tolerability and efficacy of single-dose Amg 890, a novel sirna targeting Lp(a), in healthy subjects and subjects with elevated Lp(a). Circulation. 2020;142:A13951.","journal-title":"Circulation"},{"issue":"11","key":"938_CR41","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1161\/ATVBAHA.116.308305","volume":"36","author":"A Varbo","year":"2016","unstructured":"Varbo A, Nordestgaard BG. Remnant cholesterol and triglyceride-rich lipoproteins in atherosclerosis progression and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2133\u20135.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"938_CR42","doi-asserted-by":"crossref","unstructured":"Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019 Dec 1;4(12):1287\u201395.","DOI":"10.1001\/jamacardio.2019.3780"},{"key":"938_CR43","doi-asserted-by":"crossref","unstructured":"Pouwer MG, Pieterman EJ, Worms N, Keijzer N, Jukema JW, Gromada J, et al. Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice. J Lipid Res. 2020 Mar;61(3):365\u201375.","DOI":"10.1194\/jlr.RA119000419"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-021-00938-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-021-00938-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-021-00938-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T17:16:10Z","timestamp":1625159770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-021-00938-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,19]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1007\/s11883-021-00938-z","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,19]]},"assertion":[{"value":"17 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"45"}}